NeoGenomics and Indica Labs expand on their digital pathology partnership, supporting high-volume clinical operations through a cloud-based deployment while providing a scalable foundation for future AI and companion diagnostic (CDx) initiatives.

Indica Labs, the trusted global leader in AI-powered digital pathology, today announced a significant expansion of its strategic partnership with NeoGenomics, a leading provider of oncology diagnostic solutions that enable precision medicine. The expanded collaboration is intended to modernize NeoGenomics enterprise digital pathology infrastructure, accelerate the evaluation and adoption of AI across its clinical operations and biomarker analysis, and establishes a framework for deployment of next generation of companion diagnostic (CDx) solutions.

The partnership brings together two organizations at the forefront of precision medicine: Indica Labs, with its market-leading HALO AP® image management system, extensive AI portfolio, and proven track record as the trusted platform for CDx development, and NeoGenomics, with its deep expertise in cancer genetics and diagnostics, serving  approximately 4,400 medical sites and performing over 1.7 million cancer-related tests each year, including 100,000+ NGS tests.¹ The companies  expect to generate large-scale, curated pathology datasets that can drive meaningful AI advancement while providing an integrated platform capable of supporting pharmaceutical sponsors, contract research organizations (CROs), and diagnostic developers throughout the entire drug development lifecycle.

“The most progressive laboratories are moving beyond digitization and building intelligent, enterprise-scale pathology ecosystems,” said Steven Hashagen, CEO, Indica Labs. “NeoGenomics has been an outstanding innovation partner, and this expanded collaboration is a powerful demonstration of what becomes possible when trusted AI, cloud-native infrastructure, and deep clinical expertise come together. We believe that we are building a foundation that will accelerate biomarker discovery, support pharmaceutical partners, and ultimately advance precision medicine.”

Already relying on HALO AP to support high-volume digital pathology workflows across its national laboratory network, NeoGenomics is expanding enterprise-wide access through a scalable cloud-based deployment designed to support continued organizational growth. The modernization effort will encompass a full migration of NeoGenomics’ digital pathology infrastructure and integration services to the cloud, all managed and supported by Indica Labs’ highly experienced Cloud Services team. This infrastructure investment is intended to position NeoGenomics not only for operational efficiency, but as a long-term platform for future AI deployment, clinical trial support, and companion diagnostic innovation.

“Technology investments ultimately matter because of their impact on patients,” said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics. “Our expanded partnership with Indica Labs is expected to help build our digital pathology foundation for more timely, accurate diagnostic insights that can support personalized treatment decisions and improve the experience for the patients and providers who depend on us.”

The collaboration further reinforces HALO AP’s growing role as a vendor-neutral platform for companion diagnostic development. With scanner-agnostic and reagent-agnostic architecture, enterprise scalability, and rapidly expanding global footprint, HALO AP is increasingly the platform of choice for pharmaceutical companies and diagnostic developers seeking AI solutions that can be deployed consistently and reproducibly across diverse laboratory environments worldwide.

1. NeoGenomics Laboratories. About NeoGenomics. Accessed July 21, 2026. https://www.neogenomics.com/about-neogenomics

Regulatory

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. PRR-MAR-000013v1

About Indica Labs
Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of the translational journey.

About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, providing oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated scope, timing and benefits of the expanded collaboration between Indica Labs and NeoGenomics; the planned migration of NeoGenomics’ digital pathology infrastructure to the cloud; the expected generation of curated pathology datasets; and potential future AI co-development, clinical trial and companion diagnostic initiatives. These statements reflect current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including: the ability to implement and scale the HALO AP platform across NeoGenomics’ laboratory network on the anticipated timeline and at the anticipated cost; uncertainty regarding the development, validation and commercial availability of AI-based biomarker and companion diagnostic applications; the parties’ ability to enter into future co-development or clinical trial arrangements on acceptable terms; and market acceptance of the digital pathology capabilities described. Additional risks relating to NeoGenomics are described in NeoGenomics, Inc.’s Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission, available at www.sec.gov. NeoGenomics undertakes no obligation to update any forward-looking statements relating to NeoGenomics contained in this release, except as required by applicable law.